Top Analytics Companies in Boston, MA (167)

Strong Revenue Growth: Inc. 5000 recognitions cite 82% and 72% three-year growth, and investor disclosures note meaningful 2025 revenue scale, indicating sustained multi-year expansion. While precise YoY rates aren’t public, repeated list appearances and disclosed scale point to continued momentum.

Investor Backing & Capital Strength: Nordic Capital became the majority owner in 2025 to support the next phase of growth, expansion, and platform investment. Additional financing and stated plans for strategic acquisitions further reinforce access to growth capital.

Market Expansion: Customer and data footprint expanded to 170M+ patient records across 200+ provider/payer organizations, with more than 2.25M value-based lives added in 2024. Management and media describe ambitions for further expansion via M&A and potential moves beyond the U.S.

Strong Revenue Growth: Revenue is rising at a double-digit pace, with FY2025 up about 32% to $1.234B and Q1–Q2 2026 growing roughly 28% and 26% year over year, alongside raised FY2026 guidance implying around 24% growth. Larger-account cohorts also expanded materially, reinforcing the top-line trajectory.

Customer Loyalty & Retention: Dollar-based net revenue retention was approximately 109–110%, indicating existing customers are expanding spend on the platform. Higher-value segments grew quickly as well, including customers generating over $50K in ARR rising in the mid-to-high 30% range year over year.

Market Expansion: International revenue is outpacing overall growth, including 42% growth in FY2025 and mid-30% growth in early 2026. Total customers also surpassed 205,000 globally as enterprise and multi-product adoption broadened.

Investor Backing & Capital Strength: Significant financing includes a $56.1M Series C in 2024 and additional growth-capital funding from CIBC Innovation Banking in March 2026, signaling continued investor confidence and runway. Company communications indicate these funds are directed toward product development, R&D, customer success, and sales.

Product Line Growth: Recent launches and expansions span Renewal Analytics, workers’ compensation capabilities (including a claims-triage solution), and a major expansion of the Group Health analytics platform, alongside an integrated Risk Management Life Cycle solution. This pattern points to broadening coverage across underwriting, renewals, and claims.

Customer Loyalty & Retention: Current materials highlight hundreds of enterprise deployments with very high client retention, paired with ongoing wins and deployments in 2025–26 (e.g., Community Health Options, Evolution Risk Partners, and continued 2026 additions). These signals suggest a sticky and expanding customer base.

Market Expansion: The company has scaled through the 2024 Accolite merger and the 2026 Cartesian acquisition, which broaden capabilities and extend its North American and European footprint. Hiring initiatives in India and emphasis on EMEA growth further indicate a wider geographic reach.

Innovation-Driven Growth: The organization has repositioned from digital transformation toward AI services, with recent moves explicitly adding data, analytics, and enterprise AI capabilities. This shift aligns offerings with higher-growth categories.

Diversified Customer Base: Following the Accolite combination, the firm cites serving hundreds of Fortune 1000 and high-growth clients. This signals access to a broad enterprise demand base.

Strong Hiring & Retention: Hiring and headcount are expanding, with disclosures of 15,000+ global employees, thousands of new hires, and third‑party estimates indicating continued workforce growth. Available evidence also points to active internal mobility and a recent increase in active job postings.

Market Expansion: Geographic and client footprints are broadening, with 40+ offices and 1,700+ customers across 170+ countries alongside concrete investments in new and expanded locations such as Hyderabad and Kingston. These moves indicate scaling delivery capacity in major capability centers and new regions.

Innovation-Driven Growth: The offering mix is shifting toward AI, data, technology, and platforms, including proprietary solutions and product capabilities. Strategic moves such as Salesforce-focused acquisitions and collaborations, plus a Tulip solution partnership, extend capabilities beyond traditional consulting.

Profitability: Net income rose to $6.79B in 2025 from $4.38B in 2024. The combined ratio improved materially (e.g., S&P-adjusted 89.7% in 2025 and high-80s in early 2026), indicating stronger underwriting performance.

Investor Backing & Capital Strength: Shareholders’ equity increased from about $22.2B in 2022 to $39.9B at year-end 2025 and exceeded $44B by mid-2026. External ratings actions (AM Best A affirmation in Sept 2025; S&P upgrade to A+ in July 2026) underscore improved capitalization.

Resilient & Sustainable Growth: S&P describes deliberate portfolio reshaping and expects 2–3% annual premium growth during 2026–2028. Management emphasizes disciplined, selective expansion following underwriting improvements, prioritizing durable returns over sheer volume.

Strong Revenue Growth: Subscription revenue is described as growing at a double‑digit year‑over‑year pace as of late 2023, signaling solid momentum in the core recurring model.

Customer Loyalty & Retention: Renewal rates are reported as extremely high, indicating sticky relationships and a durable subscription base.

Market Expansion: The underlying hotel‑data network has expanded materially to a larger global sample across nearly 200 countries, pointing to broader reach and scale.

Strong Revenue Growth: Historical disclosures point to outsized growth (e.g., revenue increasing 5x in 2020 and more than tripling in 2021), and one dataset estimates revenue rose from $21M in 2023 to $31.9M in 2024. Together with an expanding customer base, this indicates continued commercial momentum.

Investor Backing & Capital Strength: Funding totals about $114.5M, including a $71M Series C backed by major firms, and the company attributes a new Boston office in 2023 to continued growth. This capital base and facilities expansion suggest ample resources to scale.

Market Expansion: The company reports serving 1,000+ companies and highlights new offices and international expansion, alongside recent senior hires in revenue and engineering to support scaling. These signals point to ongoing expansion in customers, footprint, and organizational capacity.

Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.

Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.

Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.

Strong Revenue Growth: Revenue is rising at double-digit rates across recent periods, and management has increased full-year guidance, underscoring continued momentum. Growth is visible in both recent quarters and the prior year, indicating sustained top-line expansion.

Diversified Revenue Streams: Both Diagnostics and Data & Applications are expanding, with data-licensing/Insights activity increasing alongside clinical testing volumes. This mix reduces reliance on a single line of business and supports multiple growth vectors.

Strategic Partnerships: Collaborations with major biopharmaceutical companies and broader rollouts of platforms such as Next signal expanding commercial reach. Announced initiatives like a large whole‑genome dataset and work with firms including Merck reinforce external demand for the platform.

Product Line Growth: Continued expansion of the DXP across content, DAM, personalization, CDP and AI, plus ongoing 2025–26 launches, point to an actively growing portfolio. Acquisitions and AI-led releases (e.g., Monsido, updates to Acquia Source/AI) reinforce sustained product investment.

Strong Market Position & Advantage: Independent analyst coverage places the company as a Leader in DXP and highlights its enterprise Drupal positioning, indicating durable competitive standing. Thousands of organizations are reported to use its platform, underscoring entrenched market presence.

Customer Loyalty & Retention: Company retrospectives describe record renewal rates and customer expansion in 2023, signaling strong retention dynamics. These signals suggest customers are extending relationships and broadening adoption.

Strong Market Position & Advantage: The company is repeatedly positioned as a category leader in commercial real estate information and marketplaces, anchored by flagship brands like CoStar Suite, LoopNet, and Apartments.com. Its large proprietary database and research footprint are portrayed as difficult to replicate, supporting durable competitive advantage.

Strong Revenue Growth: Revenue is described as increasing at a sustained double-digit pace across many quarters, with notable year-over-year acceleration in recent full-year and quarterly results. Forward guidance also points to continued expansion, indicating momentum beyond a single period.

Investor Backing & Capital Strength: Capital return actions such as sizable share repurchases are presented as a signal of confidence and balance-sheet capacity. High liquidity is also referenced as a buffer that supports continued investment and resilience through sector headwinds.

Strong Market Position & Advantage: GE HealthCare is positioned as a top-tier global medical technology player with leadership across diagnostic imaging, ultrasound, and pharmaceutical diagnostics, supported by a very large installed base and operations in over 160 countries. Scale and portfolio breadth across major modalities and care settings are repeatedly presented as durable advantages that support recurring service, upgrades, and consumables/software revenue.

Innovation-Driven Growth: R&D investment exceeding $1B annually and an active pipeline of many products in imaging, digital health, and in vitro diagnostics indicate a sustained innovation engine. The emphasis on AI-enabled devices and new product introductions (e.g., photon-counting CT and other launches) is framed as a multi-year driver that should increase contribution to revenue over time.

Resilient & Sustainable Growth: Orders and backlog signals (book-to-bill above 1.0, growing orders, and a reported record backlog) suggest demand is keeping pace with shipments and provides forward visibility. Guidance for continued low-single-digit organic growth alongside expectations for EPS growth and meaningful free cash flow points to steady, defensible expansion rather than cyclical contraction.